Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
Tweet Send to a FriendGet Alerts OSUR Hot Sheet
Price: $4.34 -1.59%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OSUR Now!
Canaccord Genuity on Life Sciences/Biomedical Devices & Services
Analyst, Jeffrey Frelick, said, "Our diagnostics coverage universe begins releasing earnings later this week We anticipate largely in-line results across our covered companies. In our opinion, IVD companies with large customer installed bases are best positioned to benefit from expanding test menus and thus drive consumable growth, while focusing on emerging product pipelines for our early-stage companies."
"We remain bullish on diagnostic sector - Our coverage universe is up 10% for Q1/12, slightly ahead of the Dow Jones Industrial Average and in line with S&P 500. Our favorite stocks are OraSure (Nasdaq: OSUR), Cepheid (Nasdaq: CPHD), and GenMark (Nasdaq: GNMK). We continue to believe that OSUR and CPHD merit trading at premium valuations given their differentiating technologies in POC and MDx. We view GNMK as the best emerging pure play in MDx, which is currently trading at the low end of its peer group. We believe GNMK offers significant upside potential at 3.1x sales."
Frelick does see solid results from ALR, CPHD, GNMK, Gen-Probe (Nasdaq: GPRO) and Meridian Bioscience (Nasdaq: VIVO), but Quidel's (Nasdaq: QDEL) Q1 may be soft on slow flu season.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jeffrey Frelick, said, "Our diagnostics coverage universe begins releasing earnings later this week We anticipate largely in-line results across our covered companies. In our opinion, IVD companies with large customer installed bases are best positioned to benefit from expanding test menus and thus drive consumable growth, while focusing on emerging product pipelines for our early-stage companies."
"We remain bullish on diagnostic sector - Our coverage universe is up 10% for Q1/12, slightly ahead of the Dow Jones Industrial Average and in line with S&P 500. Our favorite stocks are OraSure (Nasdaq: OSUR), Cepheid (Nasdaq: CPHD), and GenMark (Nasdaq: GNMK). We continue to believe that OSUR and CPHD merit trading at premium valuations given their differentiating technologies in POC and MDx. We view GNMK as the best emerging pure play in MDx, which is currently trading at the low end of its peer group. We believe GNMK offers significant upside potential at 3.1x sales."
Frelick does see solid results from ALR, CPHD, GNMK, Gen-Probe (Nasdaq: GPRO) and Meridian Bioscience (Nasdaq: VIVO), but Quidel's (Nasdaq: QDEL) Q1 may be soft on slow flu season.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Standard & Poor's, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
